ClinicalTrials.gg
CompletedNCT03488550Updated Aug 20, 2020

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

A Phase 1 interventional study of ANX007 in Open-angle Glaucoma, sponsored by Annexon, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-20.

Sponsored by Annexon, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
267th of 279
9 · median 84
Started
2018
with 15 others
Phase 1
19 of 348
2 open now
Registered
197th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 267th largest by enrollment of the 279 interventional ones that give a count, is one of 16 that started in 2018, is one of 19 in phase 1, and was the 197th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.

Read the detailed description

This is a phase 1, open-label, dose-escalation, safety study evaluating up to 3 dose levels of ANX007 administered as single IVT injections. Approximately 9 to 15 eligible participants are enrolled into one cohort each. All participants receive ANX007 in an open-label manner. The primary objective is to evaluate the safety and tolerability of a single intravitreal (IVT) injection of ANX007 in participants with primary open-angle glaucoma. Secondary objectives are to evaluate the serum pharmacokinetics (PK) and immunogenicity. An exploratory objective will evaluate the pharmacodynamic (PD) effect of ANX007 on serum C1q activity.

03

Conditions studied

  • Open-angle Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age 18 years and older
  • Diagnosis of primary open-angle glaucoma
  • Intraocular pressure \<21 mm Hg on a stable IOP treatment regimen
  • Reliable visual field testing

Exclusion criteria

Exclusion Criteria:

  • BCVA worse than 20/80 in either eye
  • Extensive glaucomatous visual-field damage
  • History of intraocular inflammatory or infectious eye disease in study eye
  • Ocular trauma in study eye within the preceding 6 months
  • History of uncomplicated cataract surgery less than 6 mos prior
  • Any abnormality preventing reliable Tonopen tonometry in study eye
  • Active within past 5 yrs
  • Previous tx with another humanized monoclonal antibody
  • History of any or neurologic disease
  • Concurrent use of medications
  • Receiving monoamine oxidase inhibitor therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    ANX007-GLA-01

    Biological: ANX007

Interventions

  • BiologicalANX007

    Single ascending dose

06

What researchers measure

Primary outcomes

  1. Safety and tolerability as measured by the occurrence of adverse events

    Time frame: Day 56

Secondary outcomes

  1. Serum plasma concentration of ANX007 after a single IVT injection.

    Time frame: Day 15

  2. Immunogenicity of ANX007 after a single IVT injection.

    Time frame: Day 56

Other outcomes

  1. Effect of a single IVT injection of ANX007 on serum C1q

    Time frame: Day 15

07

Study locations

1 site
  • Eye Research Foundation
    Newport Beach, California 92663, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Aug 2018, 4 months.

Of 17 phase 1 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2018
First posted
Apr 5, 2018
StartActual
Mar 23, 2018
Primary completionActual
Aug 3, 2018
CompletionActual
Aug 3, 2018
Last update
Aug 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03488550
Lead sponsor
Annexon, Inc.
Responsible party
Sponsor
First posted
Apr 5, 2018
Start date
Mar 23, 2018
Primary completion
Aug 3, 2018
Completion
Aug 3, 2018
Last update
Aug 20, 2020

Study contacts

Eric Humphriss
study director · Annexon Vice President of Clinical Operations

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonaprument

Start the discussion